ZAI LAB LTD reports a Return on Equity (ROE) of -26.91%.

What is ZLAB's dividend yield?

ZAI LAB LTD offers a dividend yield of 0.00%.

What is ZLAB's Deepscope Quality Score?

Deepscope rates ZLAB's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ZLAB?

Deepscope's AI Timing Score for ZLAB is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ZLAB belong to?

ZAI LAB LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

ZLAB (NASDAQ) Stock Analysis | ZAI LAB LTD

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-08 | FS: 2026-03-31)

ZLAB

ZAI LAB LTD

US:NASDAQ STOCK Healthcare >> Biotechnology News 77

USD 16.48

-0.14 (-0.84%) Day Change

Watchlist Portfolio Compare Chart

0.33

D/E

-26.9%

ROE

-16.3%

ROA

0.00%

Div Yield

ZAI LAB LTD
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 16.48 Price -0.14 (-0.84%) Day Change	NEWS SCORE: 77

ZLAB, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	77
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	16.48
PBV / Sector	2.81 / 4.75
Earning Per Share	-1.58

PE / Sector	N/A / 17.65
PEG or PE/Growth / Sector	N/A / 0.52
Average 1M Daily Value	16.30 M GREAT
Average 1W Daily Value	19.54 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-39.29 / 468.85
NPM Average (%) / Sector	-94.70 / -1,531.69
NPM Change Average (%) / Sector	-31.39 / 5,028.65
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-16.26 / 31.69
ROA Average (%) / Sector	-24.31 / -353.18
ROA Change Average (%) / Sector	-16.59 / 5,214.65
ROE (%) / Sector	-26.91 / 10.58
ROE Average (%) / Sector	-33.29 / 27.64
ROE Change Average (%) / Sector	-9.55 / 2,048.88
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 3.97

Registration Details

Analyze Date	2026-06-09 09:40:15
Symbol	ZLAB
Name	ZAI LAB LTD
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	112.35 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,860.03 / 9,000.42

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Building B, Pudong, China, 201203

Phone: 86 21 6163 2588

Website: https://www.zailaboratory.com

Employees: 1,784

Sector: Healthcare >> Biotechnology

Description: Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.